title: Resiquimod 3M.
abstract: 3M Pharmaceuticals is developing a topical formulation of resiquimod as an immunomodulator for the potential treatment of herpes simplex virus (HSV) infections. As of September 2001, resiquimod was to be commercialized worldwide in association with Eli Lilly. Phase III trials for the treatment of HSV infection were initiated in November 2000 and were ongoing in September 2001. In October 2001, US and European filings were scheduled for 2004, and by February 2002, Lilly was anticipating launch in either 2004 or 2005. The compound has also been investigated for the potential treatment of various other diseases, including other viral infections and eczema and as a vaccine adjuvant.
authors.affiliation: ID Biomedical Corp of Quebec, 7150 Frederick Banting, Suite 200, Ville St-Laurent, Quebec H4S 2A1, Canada. tjones@intellivax.com
authors.forename: Taff
authors.initials: T
authors.lastname: Jones
mesh_terms: D000287:Administration, Topical; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000138:chemical synthesis / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D000075202:Contraindications; D004485:Eczema / Q000188:drug therapy; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000138:chemical synthesis / Q000627:therapeutic use*; D030361:Papillomavirus Infections / Q000188:drug therapy; D013329:Structure-Activity Relationship
chemical_list: D000998:Antiviral Agents; D007093:Imidazoles; C402365:resiquimod